Novartis
NEWS
In a special report published by Reuters last month, Michele Gershberg describes the painstaking medical journey of her 4-year-old son. “It was March 2017. Over the previous year, the signs had mounted that something was wrong.”
PwC recently came out with the latest version of their annual R&D spending report, and while there is a lot of interesting information to digest in this report, there are a few companies in particular that stand out within the field of biotechnology.
As 2018 comes to a close, analysts, journalists, investors and industry-watchers are studying their crystal balls to see what trends to watch in the upcoming year. Here are 7 trends most likely to be hitting the news cycle.
Using a calculation, ICER believes the Novartis gene therapy for Spinal Muscular Atrophy will be more cost effective than Biogen’s Spinraza.
Turning an existing partner into a wholly owned subsidiary, Novartis is acquiring CellforCure from biotechnology group LFB for an undisclosed figure.
Endocyte, Inc. today announced that at its Special Meeting of Stockholders held earlier today, Endocyte’s stockholders approved the adoption of the merger agreement pursuant to which Novartis AG will acquire Endocyte for $24 per share, or a total equity value of approximately $2.1 billion, in cash.
An analysis shows that more than 30 drugmakers plan to increase the price of prescription medicine in January, despite presidential rhetoric.
On Tuesday, Sandoz AG, Novartis’ subsidiary focused on generic drugs and biosimilars, teamed up with Tilray Canada, Ltd., a subsidiary of Tilray Inc. to increase availability of high quality medical cannabis products across the globe.
Although every year, big biopharma companies give up on some programs, 2018 seems like it has been marked by unusually extensive program abandonment.
JOBS
IN THE PRESS